Opinion|Videos|October 21, 2024
Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management
Key Takeaways
- Disparities in clinical guidelines and access to therapies can lead to varied treatment outcomes in uro-oncology.
- Patient adherence is influenced by treatment complexity, financial constraints, and healthcare professional support.
Panelists discuss how the differences in routes of administration, durations of therapy, and control arms among PD1/PD-L1 inhibitors in trials may impact patient care, resource utilization, and treatment adherence, highlighting key insights from recent Uro Oncology presentations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Explain how these differences may impact patient care, resource use, and adherence. [Uro Oncology presentation by Psutka]
Bedke 2023
Advertisement
Related to this article
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to pre-biopsy 68Ga-PSMA-PET program
2
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
3
Brian Mazzarella, MD, reviews early data on water vapor therapy for localized prostate cancer
4
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer
5